-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The deoxynephrine keromate solution is a compound eye solution consisting of deoxynephrine and ketone chromic acid.
The former is an alpha1-adrenaline-subject agonist that is used as a pupil amplification agent in the eye by shrinking the iris radiation muscle, and the latter is a nonsteroidal anti-inflammatory drug that inhibits cyclooxidase (COX-1 and COX-2), resulting in lower prostatin concentrations in tissues to reduce surgical pain.
time, ketone acid can prevent the pupil shrinking caused by surgery by inhibiting the synthesis of prostatins that are followed by surgical damage to the eye or direct mechanical stimulation of the iris.
the drug was first developed by Omeros, which was approved by the FDA in May 2014 for Omidria and EMA approved for listing in Europe in July 2015.
, but before Hengrui submitted its listing application, there were no domestic enterprise applications.
Henrui's project for the drug was filed and accepted in December 2015 and approved in May 2016.
, according to the Insight database, its clinical application was reviewed and approved by the Ethics Committee in July 2019 to initiate Phase III clinical practice.
the drug was declared on the market today.
from: Insight database () It is worth noting that HengRui in the field of ophthalmology in the past two years, the introduction of the first imitation.
the introduction of the drug, in November 2019, Henrik reached an agreement with Novaliq GmbH of Germany to introduce Novaliq's drug CyclASol (0.1% cyclosporine A preparation) and NOV03 (perfluorohexyl octane), which were recently approved for clinical trials of SHR8058; In terms of first imitation layout, in May and July 2020, Hengrui's glare treatment drug "teflon prostatin eye drops" and dry eye disease treatment drug "dkwa phosphate sodium eye drops" were first reported for the first time, the former was included in the priority review and approval.
this "deoxynephrine ketogenic acid solution" is the first domestic listing.
。
